Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM5D7VG)

Drug Name
Pegozafermin Drug Info
Synonyms BIO89-100
Indication
Disease Entry ICD 11 Status REF
Hypertriglyceridemia 5C80.1 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DM5D7VG

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fibroblast growth factor-21 (FGF21) TTQ916P FGF21_HUMAN Agonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Fibroblast growth factor-21 (FGF21) DTT FGF21 6.28 3.263 4.263 3.472
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Hypertriglyceridemia
ICD Disease Classification 5C80.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Fibroblast growth factor-21 (FGF21) DTT FGF21 9.68E-01 0.05 0.22
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05852431) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia (SHTG): The ENTRUST Study. U.S.National Institutes of Health.
2 Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):120-132.